Duomeda - Company finances
|
EUR
|
2023
From: 2023-01-12
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 103,067 | 47,557 | 10,640 |
| Profit before tax | 3,333 | 1,694 | -1,560 |
| Net profit | 3,333 | 1,499 | -1,560 |
| Equity | 3,335 | 1,334 | -226 |
| Liabilities | 762 | 4,165 | 3,063 |
| Non-current assets | 1,104 | 726 | 347 |
| Current assets | 2,993 | 4,773 | 2,490 |
| Total assets | 4,097 | 5,499 | 2,837 |
|
Taxes paid
|
|||
| STI taxes | 1,087 | 108 | - |
|
Financial indicators
|
|||
| Revenue change y/y | - | -53.9% | -77.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 81.4% | 27.3% | -55.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.9% | 112.4% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.2% | 3.2% | -14.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.2% | 3.6% | -14.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 3.1 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Duomeda - Social security debts
The company had no debts to Sodra
Duomeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-06-28 | 2026-07-26 | 5.02 |
| 2026-01-29 | 2026-02-27 | 0.02 |
| 2026-01-08 | 2026-01-28 | 0.05 |
| 2026-01-01 | 2026-01-07 | 46.02 |
| 2025-07-01 | 2025-07-25 | 0.02 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Duomeda, MB, company code 306219192, is a Lithuanian small partnership engaged in retail sale of other medical and orthopaedic goods. In the latest financial year, 2025, revenue fell to €10.6K from €47.6K in 2024 and €103.1K in 2023, showing a sharp two-year contraction. The company moved from modest profitability to a net loss: net profit was €3.3K in 2023, €1.5K in 2024, and -€1.6K in 2025. The latest profit margin was -14.7%. The balance sheet also weakened in 2025, with total assets of €2.8K, equity of -€226, and liabilities of €3.1K. Long-term assets stood at €347 and short-term assets at €2.5K. Asset turnover was 3.75x, indicating that revenue was generated against a relatively small asset base, but the negative equity position and loss-making result point to reduced financial stability. The latest figures suggest a business under pressure after a significant decline in turnover over 2023-2025.